The association between exposure to interferon-beta during pregnancy and birth measurements in offspring of women with multiple sclerosis


Autoři: Sarah Burkill aff001;  Pia Vattulainen aff003;  Yvonne Geissbuehler aff004;  Meritxell Sabido Espin aff005;  Catrinel Popescu aff006;  Kiliana Suzart-Woischnik aff007;  Jan Hillert aff008;  Miia Artama aff009;  Auli Verkkoniemi-Ahola aff010;  Kjell-Morten Myhr aff011;  Sven Cnattingius aff002;  Pasi Korhonen aff003;  Scott Montgomery aff002;  Shahram Bahmanyar aff001
Působiště autorů: Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden aff001;  Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden aff002;  EPID research, Helsinki, Finland aff003;  Novartis Pharma AG, Basel, Switzerland aff004;  Merck group, Darmstadt, Germany aff005;  Biogen, Maidenhead, United Kingdom aff006;  Bayer AG, Berlin, Germany aff007;  Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden aff008;  National Institute for Health and Welfare, Helsinki, Finland aff009;  Department of Neurology, Helsinki University, Helsinki, Finland aff010;  Department of Clinical Medicine, University of Bergen, Bergen, Norway aff011;  Clinical Epidemiology and Biostatistics School of Medical Sciences, Örebro University, Örebro, Sweden aff012;  Department of Epidemiology and Public Health, University College London, London, United Kingdom aff013
Vyšlo v časopise: PLoS ONE 14(12)
Kategorie: Research Article
doi: 10.1371/journal.pone.0227120

Souhrn

Background

Interferon-beta (IFN-beta) is a commonly used treatment for multiple sclerosis (MS). Current guidelines recommend cessation of treatment during pregnancy, however the results of past studies on the safety of prenatal exposure to IFN-beta have been conflicting. A large scale study of a population of MS women is therefore warranted.

Objectives

To assess whether, among those born to women with MS, infants prenatally exposed to IFN-beta show evidence of smaller size at birth relative to infants which were not prenatally exposed to any MS disease modifying drugs.

Methods

Swedish and Finnish register data was used. Births to women with MS in Sweden and Finland between 2005–2014 for which a birth measurement for weight, height, and head circumference was available were included. The exposure window was from 6 months prior to LMP to the end of pregnancy.

Results

In Sweden, 411 pregnancies were identified as exposed to IFN-beta during the exposure window, and 835 pregnancies were counted as unexposed to any MS DMD. The corresponding numbers for Finland were 232 and 331 respectively. Infants prenatally exposed to interferon-beta were on average 28 grams heavier (p = 0.17), 0.01 cm longer (p = 0.95), and had head circumferences 0.14 cm larger (p = 0.13) in Sweden. In Finland, infants were 50 grams lighter (p = 0.27), 0.02 cm shorter (p = 0.92) and had head circumferences 0.22 cm smaller (p = 0.15) relative to those unexposed.

Conclusions

This study provides evidence that exposure to IFN-beta during pregnancy does not influence birth weight, length, or head circumference.

Klíčová slova:

Birth – Birth weight – Drug therapy – Infants – Multiple sclerosis – Pregnancy – Sweden – Finland


Zdroje

1. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–86. doi: 10.1212/WNL.0000000000000560 24871874

2. Priddy KD. Immunologic adaptations during pregnancy. J Obstet Gynecol Neonatal Nurs. 1997;26(4):388–94. doi: 10.1111/j.1552-6909.1997.tb02720.x 9252886

3. Kourtis AP, Read JS, Jamieson DJ. Pregnancy and infection. The New England journal of medicine. 2014;370(23):2211–8. doi: 10.1056/NEJMra1213566 24897084

4. Hellwig K, Haghikia A, Rockhoff M, Gold R. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Ther Adv Neurol Disord. 2012;5(5):247–53. doi: 10.1177/1756285612453192 22973421

5. Sandberg-Wollheim M, Alteri E, Moraga MS, Kornmann G. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Multiple sclerosis (Houndmills, Basingstoke, England). 2011;17(4):423–30.

6. Kieseier BC, Benamor M. Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis. Neurol Ther. 2014;3(2):133–8. doi: 10.1007/s40120-014-0020-y 26000229

7. Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Multiple sclerosis (Houndmills, Basingstoke, England). 2009;15(9):1037–42.

8. Vukusic S, Marignier R. Multiple sclerosis and pregnancy in the 'treatment era'. Nature reviews Neurology. 2015;11(5):280–9. doi: 10.1038/nrneurol.2015.53 25896084

9. Reder AT, Oger JF, Kappos L, O'Connor P, Rametta M. Short-term and long-term safety and tolerability of interferon beta-1b in multiple sclerosis. Multiple sclerosis and related disorders. 2014;3(3):294–302. doi: 10.1016/j.msard.2013.11.005 25876467

10. Coyle PK, Sinclair SM, Scheuerle AE, Thorp JM Jr., Albano JD, Rametta MJ. Final results from the Betaseron (interferon beta-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events. BMJ open. 2014;4(5):e004536. doi: 10.1136/bmjopen-2013-004536 24821713

11. Boskovic R, Wide R, Wolpin J, Bauer DJ, Koren G. The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. Neurology. 2005;65(6):807–11. doi: 10.1212/01.wnl.0000180575.77021.c4 16186517

12. Mick E, Biederman J, Prince J, Fischer MJ, Faraone SV. Impact of low birth weight on attention-deficit hyperactivity disorder. Journal of developmental and behavioral pediatrics: JDBP. 2002;23(1):16–22. doi: 10.1097/00004703-200202000-00004 11889347

13. Barker DJ. Fetal origins of coronary heart disease. Bmj. 1995;311(6998):171–4. doi: 10.1136/bmj.311.6998.171 7613432

14. Jornayvaz FR, Vollenweider P, Bochud M, Mooser V, Waeber G, Marques-Vidal P. Low birth weight leads to obesity, diabetes and increased leptin levels in adults: the CoLaus study. Cardiovascular diabetology. 2016;15:73. doi: 10.1186/s12933-016-0389-2 27141948

15. Nobile CG, Raffaele G, Altomare C, Pavia M. Influence of maternal and social factors as predictors of low birth weight in Italy. BMC public health. 2007;7:192. doi: 10.1186/1471-2458-7-192 17683559

16. Fok TF, So HK, Wong E, Ng PC, Chang A, Lau J, et al. Updated gestational age specific birth weight, crown-heel length, and head circumference of Chinese newborns. Archives of disease in childhood Fetal and neonatal edition. 2003;88(3):F229–36. doi: 10.1136/fn.88.3.F229 12719398

17. de Jong CL, Francis A, van Geijn HP, Gardosi J. Fetal growth rate and adverse perinatal events. Ultrasound in obstetrics & gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 1999;13(2):86–9.

18. Thone J, Thiel S, Gold R, Hellwig K. Treatment of multiple sclerosis during pregnancy—safety considerations. Expert Opin Drug Saf. 2017;16(5):523–34. doi: 10.1080/14740338.2017.1311321 28333552

19. Neuhaus O, Kieseier BC, Hartung HP. Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis. Journal of the neurological sciences. 2007;259(1–2):27–37. doi: 10.1016/j.jns.2006.05.071 17391705

20. Machado CJ. Impact of maternal age on birth outcomes: a population-based study of primiparous Brazilian women in the city of Sao Paulo. Journal of biosocial science. 2006;38(4):523–35. doi: 10.1017/S0021932005026660 16762088

21. Yu SH, Mason J, Crum J, Cappa C, Hotchkiss DR. Differential effects of young maternal age on child growth. Global health action. 2016;9:31171. doi: 10.3402/gha.v9.31171 27852422

22. Borja JB, Adair LS. Assessing the net effect of young maternal age on birthweight. American journal of human biology: the official journal of the Human Biology Council. 2003;15(6):733–40.

23. Ergin I, Hassoy H, Tanik FA, Aslan G. Maternal age, education level and migration: socioeconomic determinants for smoking during pregnancy in a field study from Turkey. BMC public health. 2010;10:325. doi: 10.1186/1471-2458-10-325 20534133

24. Thiel S, Langer-Gould A, Rockhoff M, Haghikia A, Queisser-Wahrendorf A, Gold R, et al. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry. Multiple sclerosis. 2016;22(6):801–9. doi: 10.1177/1352458516634872 26920382

25. Juch H, Lupattelli A, Ystrom E, Verheyen S, Nordeng H. Medication adherence among pregnant women with hypothyroidism-missed opportunities to improve reproductive health? A cross-sectional, web-based study. Patient education and counseling. 2016;99(10):1699–707. doi: 10.1016/j.pec.2016.04.006 27133920

26. Bailey H, Thorne C, Malyuta R, Townsend CL, Semenenko I, Cortina-Borja M, et al. Adherence to antiretroviral therapy during pregnancy and the first year postpartum among HIV-positive women in Ukraine. BMC public health. 2014;14:993. doi: 10.1186/1471-2458-14-993 25248469


Článek vyšel v časopise

PLOS One


2019 Číslo 12